Advertisement

Clinical Research in Cardiology

, Volume 107, Supplement 2, pp 74–80 | Cite as

German contribution to development and innovations in the management of acute myocardial infarction and cardiogenic shock

  • Hans-Josef Feistritzer
  • Steffen Desch
  • Suzanne de Waha
  • Alexander Jobs
  • Uwe Zeymer
  • Holger Thiele
Review

Abstract

Treatment of acute coronary syndromes has evolved over time leading to a significantly reduced mortality. Multiple major trials have been performed in Germany leading to new treatment strategies in acute coronary syndromes including cardiogenic shock. This review article will summarize major trials and their impact on guideline recommendations in acute myocardial infarction highlighting reperfusion strategies, antiplatelet regimens, prognosis assessment and also mechanical circulatory support in stable infarction patients and in cardiogenic shock.

Keywords

Acute coronary syndrome Infarction Stent Antithrombotic treatment Cardiogenic shock 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    de Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Wellens HJ (1991) Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 18(3):698–706CrossRefPubMedGoogle Scholar
  2. 2.
    Kristensen SD, Laut KG, Fajadet J, Kaifoszova Z, Kala P, Di Mario C et al (2014) Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J 35(29):1957–1970CrossRefPubMedGoogle Scholar
  3. 3.
    Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 377(25):2419–2432CrossRefPubMedGoogle Scholar
  4. 4.
    Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287–1296CrossRefPubMedGoogle Scholar
  5. 5.
    Thiele H, Ohman EM, Desch S, Eitel I, de Waha S (2015) Management of cardiogenic shock. Eur Heart J 36(20):1223–1230CrossRefPubMedGoogle Scholar
  6. 6.
    Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol 54(4):281–292CrossRefPubMedGoogle Scholar
  7. 7.
    Zeymer U, Arntz H-R, Mark B, Fichtlscherer S, Werner G, Schöller R et al (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101(4):305–312CrossRefPubMedGoogle Scholar
  8. 8.
    Montalescot G, van ’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371(11):1016–1027CrossRefPubMedGoogle Scholar
  9. 9.
    Zeymer U, Hohlfeld T, vom Dahl J, Erbel R, Münzel T, Zahn R et al (2017) Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i.v. and 300 mg p.o. in ACS (ACUTE). Thromb Haemostasis 117(3):625 – 35CrossRefGoogle Scholar
  10. 10.
    Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119 – 77CrossRefPubMedGoogle Scholar
  11. 11.
    Zeymer U, Margenet A, Haude M, Bode C, Lablanche J-M, Heuer H et al (2010) Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial. J Am Coll Cardiol 56(6):463–469CrossRefPubMedGoogle Scholar
  12. 12.
    Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B et al (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379(9819):923–931CrossRefPubMedGoogle Scholar
  13. 13.
    Eitel I, Wohrle J, Suenkel H, Meissner J, Kerber S, Lauer B et al (2013) Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol 61(13):1447–1454CrossRefPubMedGoogle Scholar
  14. 14.
    Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M et al (2011) Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 365(21):1980–1989CrossRefPubMedGoogle Scholar
  15. 15.
    Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J et al (1993) A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 328(10):673–679CrossRefPubMedGoogle Scholar
  16. 16.
    Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP et al (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341(19):1413–1419CrossRefPubMedGoogle Scholar
  17. 17.
    Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J et al (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 343(6):385–391CrossRefPubMedGoogle Scholar
  18. 18.
    Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J et al (2002) Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 359(9310):920–925CrossRefPubMedGoogle Scholar
  19. 19.
    Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP et al (2009) Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 360(21):2165–2175CrossRefPubMedGoogle Scholar
  20. 20.
    Thiele H, Rach J, Klein N, Pfeiffer D, Hartmann A, Hambrecht R et al (2012) Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). Eur Heart J 33(16):2035–2043CrossRefPubMedGoogle Scholar
  21. 21.
    Jobs A, Mehta SR, Montalescot G, Vicaut E, van’t Hof AW, Badings EA et al (2017) Optimal timing of invasive strategy in patients with non-ST-elevation acute coronary syndrome: a collaborative meta-analysis of randomised trials. Lancet 390:737–746CrossRefPubMedGoogle Scholar
  22. 22.
    Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315CrossRefPubMedGoogle Scholar
  23. 23.
    Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B et al (2014) Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial. J Am Coll Cardiol 64(11):1117–1124CrossRefPubMedGoogle Scholar
  24. 24.
    Meyer-Saraei R, de Waha S, Eitel I, Desch S, Scheller B, Bohm M et al (2017) Thrombus aspiration in non-ST-elevation myocardial infarction – 12-month clinical outcome of the randomised TATORT-NSTEMI trial. Eur Heart J Acute Cardiovasc Care 6(1):10–17CrossRefPubMedGoogle Scholar
  25. 25.
    Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F et al (2017) Thrombus aspiration in ST-segment–elevation myocardial infarction. An individual patient meta-analysis: thrombectomy trialists collaboration. Circulation 135(2):143–152CrossRefPubMedGoogle Scholar
  26. 26.
    Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T et al (2016) Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. Clin Res Cardiol 105(7):575–584CrossRefPubMedGoogle Scholar
  27. 27.
    Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G et al (2001) The Na+/H + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 38:1644–1650CrossRefPubMedGoogle Scholar
  28. 28.
    Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N et al (2015) Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J 36(44):3049–3057CrossRefPubMedGoogle Scholar
  29. 29.
    Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S et al (2017) Early diagnosis of acute coronary syndrome. Eur Heart J 38(41):3049–3055CrossRefPubMedGoogle Scholar
  30. 30.
    Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T (1997) Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 337(23):1648–1653CrossRefPubMedGoogle Scholar
  31. 31.
    Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM et al (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab antiplatelet therapy in unstable refractory angina (CAPTURE) Study Investigators. N Engl J Med 340(21):1623–1629CrossRefPubMedGoogle Scholar
  32. 32.
    Keller T, Zeller T, Ojeda F, Tzikas S, Lillpopp L, Sinning C et al (2011) Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 306(24):2684–2693CrossRefPubMedGoogle Scholar
  33. 33.
    Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361(9):868–877CrossRefPubMedGoogle Scholar
  34. 34.
    Schroder K, Wegscheider K, Zeymer U, Tebbe U, Schroder R (2001) Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet 358(9292):1479–1486CrossRefPubMedGoogle Scholar
  35. 35.
    Schroder R (2004) Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110(21):e506-10CrossRefPubMedGoogle Scholar
  36. 36.
    Eitel I, de Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M et al (2014) Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 64(12):1217–1226CrossRefPubMedGoogle Scholar
  37. 37.
    de Waha S, Desch S, Eitel I, Fuernau G, Zachrau J, Leuschner A et al (2010) Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J 31:2660–2668CrossRefPubMedGoogle Scholar
  38. 38.
    de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I et al (2017) Relationship between microvascular obstruction and adverse events following primary PCI for STEMI: An individual patient data pooled analysis from 7 randomised trials. Eur Heart J 38:3502–3510CrossRefPubMedGoogle Scholar
  39. 39.
    Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341(9):625 – 34CrossRefPubMedGoogle Scholar
  40. 40.
    Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P et al (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295(21):2511–2515CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M et al (2004) Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 25(4):322–328CrossRefPubMedGoogle Scholar
  42. 42.
    Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J et al (2018) Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 39(13):1065–1074CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Stegman BM, Newby LK, Hochman JS, Ohman EM (2012) Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: Is therapeutic hypothermia one possibility? J Am Coll Cardiol 59(7):644–647CrossRefPubMedGoogle Scholar
  44. 44.
    Fuernau G, Beck J, Desch S, Eitel I, Erbs S, Mangner N et al. Mild hypothermia in cardiogenic shock complicating myocardial infarction—the randomized SHOCK-COOL pilot trial. Eur Heart J. 2016;Abstract Supplement:P5199Google Scholar
  45. 45.
    Shah M, Patnaik S, Patel B, Ram P, Garg L, Agarwal M et al (2018) Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clin Res Cardiol 107(4):287–303CrossRefPubMedGoogle Scholar
  46. 46.
    Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J et al (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382(9905):1638–1645CrossRefPubMedGoogle Scholar
  47. 47.
    de Waha S, Graf T, Desch S, Fuernau G, Eitel I, Pöss J et al (2017) Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock. Clin Res Cardiol 106(5):379–385CrossRefPubMedGoogle Scholar
  48. 48.
    Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand WK et al (2016) Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 42(12):1922–1934CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S et al (2017) Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 38:3523–3531CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hans-Josef Feistritzer
    • 1
  • Steffen Desch
    • 1
    • 2
  • Suzanne de Waha
    • 2
    • 3
  • Alexander Jobs
    • 2
    • 3
  • Uwe Zeymer
    • 4
  • Holger Thiele
    • 1
  1. 1.Department of Internal Medicine/CardiologyHeart Center Leipzig – University HospitalLeipzigGermany
  2. 2.German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/LuebeckLübeckGermany
  3. 3.Department of Internal Medicine/Cardiology/Angiology/Intensive Care MedicineUniversity Heart Center LübeckLübeckGermany
  4. 4.Klinik für Innere Medizin/KardiologieKlinikum LudwigshafenLudwigshafenGermany

Personalised recommendations